Efavirenz/lamivudine/tenofovir disoproxil fumarate tablets - Macleods Pharmaceuticals

Drug Profile

Efavirenz/lamivudine/tenofovir disoproxil fumarate tablets - Macleods Pharmaceuticals

Alternative Names: Efavirenz/tenofovir disoproxil fumarate/lamivudine tablets - Macleods Pharmaceuticals; Lamivudine/efavirenz/tenofovir disoproxil fumarate tablets - Macleods Pharmaceuticals; Lamivudine/tenofovir disoproxil fumarate/efavirenz tablets - Macleods Pharmaceuticals; Tenofovir disoproxil fumarate/efavirenz/lamivudine tablets - Macleods Pharmaceuticals; Tenofovir disoproxil fumarate/lamivudine/efavirenz tablets - Macleods Pharmaceuticals

Latest Information Update: 05 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Macleods Pharmaceuticals
  • Class Antiretrovirals; Benzoxazines; Deoxyribonucleosides; Dideoxynucleosides; Phosphonic acids; Purines; Pyrimidine nucleosides
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration HIV-1 infections

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top